Research across Orthomyxoviridae Infections
Related studies from across the Orthomyxoviridae Infections family.
11 trials tracked for Avian Influenza: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 8 citations.
Showing the 11 most-cited and recently-updated of 11 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Multiple trials evaluated the immunogenicity of various influenza vaccine candidates, including those targeting H5N1 and H7N9. For H5N1-specific vaccines, studies demonstrated varying levels of success in achieving Hemagglutination Inhibition (HAI) titers of 1:40 or greater; for example, one study showed a range of 13.0% to 95.0% across different age cohorts 2, while another reported seroconversion rates between 38% and 51% following the second vaccination 8.
Vaccines targeting H7N9 consistently demonstrated significant immunogenicity. Trials using the AS03 adjuvant showed HAI seroconversion rates ranging from 38% to 65% [7, 8] and neutralizing antibody seroconversions of up to 82% 8. Other H7N9 vaccine studies reported high rates of neutralizing antibody titers (up to 100%) and varying levels of HAI seroconversion across different study arms [4, 5, 6].
Specific trial data for the IVACFLU-A/H5N1 vaccine showed that a significant portion of participants achieved at least a 4-fold increase in HAI titers after vaccination, with rates reaching up to 93% 1.
AI synthesis of 6 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
Related studies from across the Orthomyxoviridae Infections family.